e8vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 22, 2008
EPIX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
|
000-21863
|
|
04-3030815 |
|
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
|
|
|
4 Maguire Road, Lexington, Massachusetts
|
|
02421 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (781) 761-7600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01 Regulation FD Disclosure.
On December 22, 2008, EPIX Pharmaceuticals, Inc. (the Company) issued a press release
announcing that the U.S. Food and Drug Administration (FDA) has approved for marketing its novel
blood pool magnetic resonance angiography agent, Vasovist® (gadofosveset trisodium), to evaluate
aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease. The
full text of the press release issued in connection with the announcement is attached as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished
and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On December 22, 2008, the Company received approval from the FDA to market its novel
blood pool magnetic resonance angiography agent, Vasovist® (gadofosveset trisodium), to evaluate
aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.
Item 9.01 Financial Statements and Exhibits.
|
|
|
(d)
|
|
Exhibits: |
|
|
|
|
|
99.1 Press Release issued by the registrant on December 22, 2008, furnished herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
EPIX PHARMACEUTICALS, INC.
|
|
December 23, 2008 |
By: |
/s/ Kim Cobleigh Drapkin
|
|
|
|
Kim Cobleigh Drapkin |
|
|
|
Chief Financial Officer |
|
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
|
99.1
|
|
Press Release issued by the registrant on December 22, 2008, furnished herewith. |